Ionetix, Precision Molecular ink supply deal

By staff writers

January 28, 2022 -- Cyclotron technology developer Ionetix and imaging biomarker and theranostics firm Precision Molecular (PMI) have signed a supply deal for the therapeutic isotope astatine-211.

Under the deal, Ionetix will supply astatine-211 to PMI in support of the firm's clinical development of targeted alpha therapies. PMI is currently developing PMI21, an astatine-211-labeled inhibitor of prostate-specific membrane antigen (PSMA). Clinical trials for PMI21 are expected to begin later this year in patients with metastatic prostate cancer, according to the firms.

Ionetix plans to commission a new facility this year in Lansing, MI, dedicated to the manufacturing and distribution of alpha-emitting radioisotopes, including astatine-211.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking